Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nordic Nanovector ASA ( (DE:8NN) ) just unveiled an announcement.
Thor Medical ASA has announced the allocation of restricted share units (RSUs) to its board members following approval at the recent annual general meeting. This move allows board members to receive their remuneration in the form of RSUs, aligning their interests with the company’s performance and potentially impacting the company’s governance and financial strategies.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier in the radiopharmaceutical industry, focusing on the production of radionuclides, particularly alpha particle emitters derived from naturally occurring thorium. The company boasts a proprietary production process that eliminates the need for irradiation or nuclear reactors, ensuring a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters. Thor Medical is based in Oslo, Norway, and is publicly traded on the Oslo Stock Exchange under the ticker ‘TRMED’.
YTD Price Performance: -11.82%
Average Trading Volume: 9,979
Technical Sentiment Signal: Hold
Current Market Cap: €60.94M
Find detailed analytics on 8NN stock on TipRanks’ Stock Analysis page.